bispecific antibodies

Photo
News

Dren Bio, Novartis to Develop Bispecific Cancer Antibodies

US biopharmaceutical company Dren Bio, a developer of novel antibody therapeutics, has entered into a collaboration with Novartis Pharma, a subsidiary of Novartis. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary targeted myeloid engager and phagocytosis platform.

Photo
News

J&J Acquires Rights to Numab's Bispecific Antibody NM26

US healthcare giant Johnson & Johnson (J&J) agreed to acquire Yellow Jersey Therapeutics (YJT) from biotechnology company Numab Therapeutics in an all-cash transaction valued at approximately $1.25 billion, giving it worldwide rights to the novel, investigational bispecific antibody NM26.

Top-Feature

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Johnson & Johnson
Photo
Bio-Rad Laboratories